Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community. The pitch is published UNEDITED and is the opinion of the CAPS member whose pitch it is, in this case: zzlangerhans.
Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, the Motley Fool's 180,000-member free investing community. Want your idea considered for this series? Make a compelling pitch on CAPS with a minimum length of 400 words. Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.
|Submitted On||Feb. 3, 2012|
|Stock Price At Underperform Recommendation:||$7.54|
Anacor Pharmaceuticals profile
|CAPS Rating (out of 5)||**|
|Headquarters||Palo Alto, Calif.|
|Market Cap||$206 million|
Sources: S&P Capital IQ, Yahoo! Finance, and Motley Fool CAPS
Is the amazing upward move in baby biotech so far this year for real? Maybe for some like Medivation and Regeneron it is, but my experience with these stocks over the last five years has taught me to maintain a healthy skepticism. On the other hand, I'm trying to avoid the mistake I've made in the past of red thumbing stocks just because the share price exploded without carefully reevaluating all their prospects-see Pharmasset, Achillion, and quite a few others.
I'm thumbing through my list of 2012 runners on a regular basis trying to separate the wheat from the chaff. One company that's looking decidedly chaffy is Anacor, the subject of a GBMB recommendation just six months ago. I suggested buying below 5.5, and the share price dropped as low as 4.33 in the midst of last August's decline. I never bought, since Anacor was one of my more speculative picks and I was fearful of a much more severe broad meltdown. The share price is now flirting with 7.5 after a 2011 replete with somewhat flimsy phase II data and I'm just not buying it.
As I've previously written, phase IIb data for AN2728 in psoriasis was decidedly weak. Best results were seen at day 42 showing 26% success with AN2728 vs 18% with placebo. By the end of treatment on day 84, the difference was only 17% vs 14%. The trial was not powered to detect statistical significance. The FDA has given the company clearance to proceed with phase III trials, but they have not yet stated if they will do so.
In 12/11 the company announced positive preliminary results of the phase IIa trial of AN2728 and AN2898 in atopic dermatitis. After 28 days of treatment the ADSI score was improved in 64% lesions treated with AN2728 vs 24% lesions treated with vehicle, and 71% receiving AN2898 vs 14% with vehicle. Lesions treated with AN2898 showed a 68% mean improvement in ADSI score compared to a 45% mean improvement in ADSI score for lesions treated with vehicle. However, if only 14% of patients receiving vehicle showed any improvement, it is hard to see how the mean improvement could have been 45%. All results were stat sig but groups were very small. The company will complete the trial analysis in early 2012 and then decide on subsequent development plans.
Meanwhile, phase III trials of tavaborole (AN2690) for onchomycosis have progressed with both trials having likely completed enrollment. Data from phase IIb trials of GSK2251052 (formerly AN3365) in cUTI and cIAI is expected later this year.
There is certainly potential for me to be wrong about this pick and pay a heavy price in CAPS points. Taken together, the pipeline has potential. However, I'm not seeing any one candidate that is likely to become a strong revenue driver in the near future, given the weakness of the dermatologic data and the questionable commercial potential of antibiotics. I expect that if this counterintuitive pharmaceutical bull market turns, Anacor's share price may be one of the first victims
Foolish bottom line
While this CAPS All-star thinks you should avoid Anacor, for a stock you don't have to avoid, check out our brand new free report on a medical device company Motley Fool analysts believe will be "The Next Rule-Breaking Multibagger."
The Motley Fool is investors writing for investors. Dan Dzombak did not have a position in any of the companies mentioned in this article. Pitches must be compelling, made in the past 30 days, and be at least 400 words. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.